Brijesh Mishra

Dr. Brijesh Mishra

Scientist

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 December 2017 in Therapeutic Advances in Endocrinology and Metabolism
Verified
Journal Article
Open access
ARAlok Raghav
Alok Raghav
Zeeshan KhanZeeshan Khan
Zeeshan Khan
RLRajendra Kumar Labala
Rajendra Kumar Labala
JAJamal Ahmad
Jamal Ahmad
SNSaba Noor
Saba Noor
BMBrijesh Mishra
Brijesh Mishra
Diabetic foot complications are the most common occurring problems throughout the globe, resulting in devastating economic crises for the patients, families and society. Diabetic foot ulcers (DFUs) have a neuropathic origin with a progressive prevalence rate in developing countries compared with developed countries among diabetes mellitus patients. Diabetic patients that are of greatest risk of ulcers may easily be diagnosed with foot examination. Economic burden may be carefully examined. The budget costing must include both the clinical and social impact of the patients.

7 March 2021 in Cells
Verified
Journal Article
Open access
PDF file
Alok RaghavAlok Raghav
Alok Raghav
Zeeshan KhanZeeshan Khan
Zeeshan Khan
VUViabhav Kumar Upadhayay
Viabhav Kumar Upadhayay
PTPrashant Tripathi
Prashant Tripathi
KGKirti Amresh Gautam
Kirti Amresh Gautam
Goo-Bo JeongGoo-Bo Jeong
Goo-Bo Jeong
The novel coronavirus severe acute respiratory syndrome-CoV-2 (SARS-CoV-2) is responsible for COVID-19 infection. The COVID-19 pandemic represents one of the worst global threats in the 21st century since World War II. This pandemic has led to a worldwide economic recession and crisis due to lockdown. Biomedical researchers, pharmaceutical companies, and premier institutes throughout the world are claiming that new clinical trials are in progress. During the severe phase of this disease, mechanical ventilators are used to assist in the management of outcomes; however, their use can lead to the development of pneumonia. In this context, mesenchymal stem cell (MSC)-derived exosomes can serve as an immunomodulation treatment for COVID-19 patients. Exosomes possess anti-inflammatory, pro-angiogenic, and immunomodulatory properties that can be explored in an effort to improve the outcomes of SARS-CoV-2-infected patients. Currently, only one ongoing clinical trial (NCT04276987) is specifically exploring the use of MSC-derived exosomes as a therapy to treat SARS-CoV-2-associated pneumonia. The purpose of this review is to provide insights of using exosomes derived from mesenchymal stem cells in management of the co-morbidities associated with SARS-CoV-2-infected persons in direction of improving their health outcome. There is limited knowledge of using exosomes in SARS-CoV-2; the clinicians and researchers should exploit exosomes as therapeutic regime.

1 December 2021 in Diabetes Research and Clinical Practice
Verified
Journal Article
Closed access
BMBrijesh Mishra
Brijesh Mishra
SMSri Venkata Madhu
Sri Venkata Madhu
MAMohd Aslam
Mohd Aslam
VAV. Agarwal
V. Agarwal
BBB.D. Banerjee
B.D. Banerjee

19 May 2018 in Diabetes & Metabolic Syndrome: Clinical Research & Reviews
Verified
Journal Article
Closed access
SMSri Venkata Madhu
Sri Venkata Madhu
GSG. Sandeep
G. Sandeep
BMBrijesh Mishra
Brijesh Mishra
MAM. Aslam
M. Aslam

2 April 2019 in Experimental Physiology
Verified
Journal Article
Closed access
PDF file
KKKeithellakpam Kiranmala
Keithellakpam Kiranmala
MAMohammad Aslam
Mohammad Aslam
BMBrijesh Mishra
Brijesh Mishra
RJRajat Jhamb
Rajat Jhamb
SMSri Venkata Madhu
Sri Venkata Madhu

1 November 2018 in Diabetes & Metabolic Syndrome: Clinical Research & Reviews
Verified
Journal Article
Closed access
BMBrijesh Mishra
Brijesh Mishra
PSP. Shukla
P. Shukla
MAM. Aslam
M. Aslam
ASA.A. Siddiqui
A.A. Siddiqui
SMSri Venkata Madhu
Sri Venkata Madhu